Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Asian Biomedicine
Volume 15 (2021): Issue 4 (August 2021)
Open Access
Potential of amentoflavone with antiviral properties in COVID-19 treatment
Akhilesh Vikram Singh
Akhilesh Vikram Singh
| Aug 20, 2021
Asian Biomedicine
Volume 15 (2021): Issue 4 (August 2021)
About this article
Previous Article
Next Article
Abstract
Article
Figures & Tables
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Article Category:
Mini review
Published Online:
Aug 20, 2021
Page range:
153 - 159
DOI:
https://doi.org/10.2478/abm-2021-0020
Keywords
amentoflavone
,
COVID-19
,
CYP450 inhibitor
,
flavonoid
,
SARS-CoV
© 2021 Akhilesh Vikram Singh, published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Figure 1
Molecular docking showing the binding of amentoflavone to the receptor binding domain of spike glycoprotein of SARS-CoV-2 (Research Collaboratory for Structural Bioinformatics Protein (RCSB) Data Base ID 6M17, chain E). Residues of the receptor binding domain interacting with amentoflavone are shown in yellow. Adapted from Miroshnychenko KV, Shestopalova A. Combined use of amentoflavone and ledipasvir could interfere with binding of spike glycoprotein of SARS-CoV-2 to ACE2: the results of molecular docking study. ChemRxiv. Preprint. doi: 10.26434/chemrxiv.12377870.v1, with kind permission of the authors. ACE2, angiotensin-converting enzyme 2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Figure 2
Interaction of amentoflavone with the inflammatory network and CYPs. Network drawn using STITCH showing chemical–protein interactions based on literature. In the network, nodes are proteins or chemicals and the edges represent the functional associations. The grey edges represent confidence with the line thickness indicating the strength of data support. Adapted from http://stitch.embl.de [25]. Inset shows the binding of amentoflavone to SARS-CoV 3CLpro. Adapted minimally and reprinted from [17] Bioorganic and Medicinal Chemistry, 18, Young Bae Ryu, Hyung Jae Jeong, Jang Hoon Kim, Young Min Kim, Ji-Young Park, Doman Kim, Thi Thanh Hanh Naguyen, Su-Jin Park, Jong Sun Chang, Ki Hun Park, Mun-Chual Rho, Woo Song Lee, Biflavonoids from Torreya nucifera displaying SARS-Co V 3CLpro inhibition, page 7944, Copyright (2010), with permission from Elsevier. The network shows the association of amentoflavone with CYPs and the inflammatory pathway to support the hypothesis for using amentoflavone as an adjunct therapy for COVID-19. 3CLpro, 3-chymotrypsin-like protease; COVID-19, Coronavirus disease-2019; CYP, cytochrome P450; ERBB2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2; GRB2, growth factor receptor-bound protein 2; HSP90AA1, heat shock protein 90α family class A member 1; IL1B, interleukin 1β; IL6, interleukin 6; IL6R, interleukin 6 receptor; IL6ST, interleukin 6 signal transducer; OPRD1, opioid receptor δ1; OPRM1, opioid receptor μ1; PPARG, peroxisome proliferator-activated receptor γ; SARS-CoV, severe acute respiratory syndrome coronavirus; TNF, tumor necrosis factor α.
Preview